By Alex Eule
| Wednesday, April 29
Health Comes First. Jerome
Powell's news conferences usually count as the most important remarks of
the day for investors. On Wednesday, though, the Federal Reserve
chairman was easily overshadowed. During a White House event, Anthony
Fauci told reporters that a potential Covid-19
treatment from Gilead Sciences "has a clear-cut, significant positive
effect in diminishing the time to recovery."
Fauci, the
head of the National
Institute of Allergy and Infectious Diseases, was
expanding on the positive news released earlier in the day by Gilead.
The company said its drug remdesivir was shortening recovery
times for Covid-19 patients in trials.
By the time Jerome Powell spoke at 2:30 p.m. ET, the S&P
500 was already up 2.7%. His remarks did
little to change the market's direction, despite their clear support for
ongoing accommodative policies. While leaving interest rates unchanged at
0% to 0.25%, Powell said, "We will continue to use our tools to assure
that the recovery, when it comes, will be as robust as possible."
But for now,
the Fed's toolbox hardly matters. Investors -- and everyone else -- are
more interested in efforts from the medical community. On that front, Wednesday
was a good day. In his White House comments, Fauci said remdesivir's initial
success carried a crucial message: "What it has proven is that a drug can
block this virus."
That's the
news we've been waiting to hear since coronavirus began taking lives and
shutting down economies across the globe. If a treatment can reduce
the deadliness of Covid-19, it would change the equation for reopening the
economy and restore some sense of normalcy in the coming months.
But the reality of the
situation isn't going to change overnight -- and the next reminder is on its
way first thing tomorrow, when the U.S. Labor Department announces the next
round of weekly jobless numbers. Economists are forecasting another 3.3 million
unemployment claims, on top of the 26 million we've already seen since the
Covid-19 shutdowns began.
No comments:
Post a Comment